Mass Spectrometry-Based Metabolic Profiling of Urinary Metabolites of N ′-Nitrosonornicotine (NNN) in the Rat
Chemical Research in Toxicology · 2023
DOI: 10.1021/acs.chemrestox.3c00025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Research in Toxicology, 2023. Verfasst von Yupeng Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, United States. Hauptthemen laut MEDLINE: Nitrosamines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
The tobacco-specific nitrosamine N'-nitrosonornicotine (NNN) and its close analogue 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) are classified as "carcinogenic to humans" (Group 1) by the International Agency for Research on Cancer. The currently used biomarker to monitor NNN exposure is urinary total NNN (free NNN plus its N-glucuronide). However, total NNN does not provide information about the extent of metabolic activation of NNN as related to its carcinogenicity. Targeted analysis of the major metabolites of NNN in laboratory animals recently led to the identification of N'-nitrosonornicotine-1N-oxide (NNN-N-oxide), a unique metabolite detected in human urine that is specifically formed from NNN. To further investigate NNN urinary metabolites that hold promise as new biomarkers for monitoring NNN exposure, uptake, and/or metabolic activation, we conducted a comprehensive profiling of NNN metabolites in the urine of F344 rats treated with NNN or [pyridine-d4]NNN. Using our optimized high-resolution mass spectrometry (HRMS)-based isotope-labeling method, 46 putative metabolites were identified with robust MS evidence. Out of the 46 candidates, all known major NNN metabolites were identified and structurally confirmed by comparing them to their isotopically labeled standards. More importantly, putative metabolites considered to be exclusively formed from NNN were also identified. The two new representative metabolites─4-(methylthio)-4-(pyridin-3-yl)butanoic acid (23, MPBA) and N-acetyl-S-(5-(pyridin-3-yl)-1H-pyrrol-2-yl)-l-cysteine (24, Py-Pyrrole-Cys-NHAc) ─were identified by comparing them to synthetic standards that were fully characterized by nuclear magnetic resonance and HRMS. They are hypothesized to be formed by NNN α-hydroxylation pathways and thus represent the first potential biomarkers to specifically monitor the uptake plus metabolic activation of NNN in tobacco users.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, United States.
- Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States.
- Division of Environmental Health Sciences, School of Public Health, University of Minnesota, Minneapolis, Minnesota 55455, United States.
ORCID-Profile: Yupeng Li, Romel P Dator, Silvia Balbo, Stephen S Hecht
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Li, Y., Dator, R. P., Maertens, L. A., Balbo, S., & Hecht, S. S. (2023). Mass Spectrometry-Based Metabolic Profiling of Urinary Metabolites of N ′-Nitrosonornicotine (NNN) in the Rat. Chemical Research in Toxicology. https://doi.org/10.1021/acs.chemrestox.3c00025
Vancouver
Li Y, Dator RP, Maertens LA, Balbo S, Hecht SS. Mass Spectrometry-Based Metabolic Profiling of Urinary Metabolites of N ′-Nitrosonornicotine (NNN) in the Rat. Chemical Research in Toxicology. 2023. doi:10.1021/acs.chemrestox.3c00025
BibTeX
@article{Li2023,
author = {Li, Yupeng and Dator, Romel P and Maertens, Laura A and Balbo, Silvia and Hecht, Stephen S},
title = {Mass Spectrometry-Based Metabolic Profiling of Urinary Metabolites of N ′-Nitrosonornicotine (NNN) in the Rat},
journal = {Chemical Research in Toxicology},
year = {2023},
doi = {10.1021/acs.chemrestox.3c00025}
}
EUVIMED